Pharmacovigilance Challenges of COVID-19 Vaccine

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccination Optimization".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 51

Special Issue Editors


E-Mail Website
Guest Editor
Centre Régional de Pharmacovigilance et D’Information sur les Médicaments, Centre Hospitalier Universitaire de Besançon, 25000 Besançon, France
Interests: pharmacovigilance; pharmaco-epidemiology; vaccine; infectious diseases; immunology; medication errors

E-Mail Website
Guest Editor
Coalition for Epidemic Preparedness Innovations, London, UK
Interests: vaccine safety; pharmacovigilance; adversomics

Special Issue Information

Dear Colleagues,

The COVID-19 pandemic challenged all healthcare systems, which had to find ways to treat the disease and prevent its spread. Pharmaceutical companies faced the challenge of developing new vaccines, and health authorities had to evaluate them and authorize their release to the market. Once the vaccines were distributed, each country had to decide how to distribute them, educate healthcare professionals on their administration, and establish a proactive surveillance system to detect any potential safety issues.

The success of the vaccination campaign depended on the collaboration of the whole of society. This Special Issue aims to provide an overview of all aspects of the pharmacovigilance system that was put in place and is still in action, as well as future perspectives.

We welcome original papers, reviews, and studies that deal with the pharmacovigilance system, safety signals, immunology mechanisms, medication errors, and the past and future challenges related to COVID-19 vaccination.

Dr. Marie-Blanche Valnet-Rabier
Dr. Rebecca Chandler
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pharmacovigilance
  • vaccine
  • vaccine safety
  • signals
  • medication errors
  • health system improvement
  • immunology

Published Papers

This special issue is now open for submission.
Back to TopTop